FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968956918> ?p ?o ?g. }

• W2968956918 endingPage "1061" @default.
• W2968956918 startingPage "1057" @default.
• W2968956918 abstract "In healthy subjects, mean pulmonary arterial pressure (mPAP) is 14.0 ± 3.3 mmHg1 with an upper limit of normal 20 mmHg.2 However, the initial World Health Organization conference on pulmonary hypertension (PH) in 1973 established that the diagnostic mPAP threshold for PH was 25 mmHg, which was based mainly on consensus opinion.3 Since that decision, most studies on PH epidemiology, diagnosis and therapy have used this ‘classical’ definition of mPAP > 25 mmHg, but the main focus of these efforts was on patients with advanced stage pulmonary vascular disease (PVD).4 On the other hand, some earlier studies suggested that even a mild increase in mPAP may be clinically important.5, 6 More recent robust epidemiological data from numerous populations worldwide have clearly demonstrated that mPAP exceeding 19 mmHg is prognostically relevant.7-13 Modifying the approach to capturing PH patients early has important implications on risk stratification, clinical trial design, and the management of patients. This recognition also led to lowering the mPAP threshold in the suggested haemodynamic definition of PH according to the Proceedings of the 6th World Symposium on Pulmonary Hypertension.14 In this new definition, pre-capillary PH is defined by a mPAP > 20 mmHg, a pulmonary arterial wedge pressure (PAWP) of ≤ 15 mmHg and a pulmonary vascular resistance of ≥ 3 Wood Units (WU), while post-capillary PH is defined by mPAP > 20 mmHg and PAWP > 15 mmHg. These changes in the haemodynamic definitions of PH have raised several questions regarding the causes, the clinical relevance and the optimal management of mildly elevated mPAP. In this viewpoint we aim to discuss established knowledge, major controversies, evidence gaps and open questions requiring further research in this field. Definitions used in the literature to characterize mildly elevated mPAP have been inconsistent. In some studies, for example, the median mPAP of the cohort under investigation was used to divide patients into two groups when doing so corresponded to differences in clinical outcome.5, 6 Published mPAP thresholds derived using this approach (e.g. 17 mmHg), have, in turn, been proposed as relevant to prognosis. Another approach used a pre-defined mPAP threshold set at the upper limit of normal (20 mmHg) and analysed if study subjects above this threshold, but < 25 mmHg, differed by clinical profile and prognosis compared with the mPAP ≤ 20 mmHg subgroup.9-11, 15, 16 A third method aimed to utilise unbiased methodologies for determining mPAP thresholds indicating worse prognosis.7, 10 In one such study, a branch-chain logic algorithm was used to determine that mPAP ≥ 17 mmHg at rest corresponded to poor prognosis in patients with exercise dyspnoea or risk for PH, although this association was dependent on age and co-morbidities.10 In another study involving a national cohort of veterans referred for right heart catheterization (> 21 000), investigators leveraged sufficient statistical power to model mPAP as a continuous variable. From this analysis, an association between mortality and mPAP emerged beginning at 19 mmHg, and increased continuously until mPAP ∼60 mmHg, suggesting that there is probably no single optimal cutoff but a gradually increasing risk relative to pulmonary arterial pressure.7 Based on these collective data, probably the best threshold to indicate a clinically relevant, age-independent mPAP elevation is around 19–20 mmHg. A mild increase in mPAP is clinically relevant due to several reasons. First, this haemodynamic profile is an independent risk factor for clinical symptoms, such as exercise dyspnoea,17 indicating its subjective importance for patients. This is consistent with a converging line of data showing that mildly elevated mPAP correlates strongly with an abnormal haemodynamic response to exercise,17-19 as well as right ventricular dysfunction assessed echocardiographically.20 Second, a mild elevation in mPAP is associated with important clinical outcome events including diminished exercise capacity10, 16, 17 and time to hospitalization.5 These parameters are often used as endpoints in clinical trials and are widely considered to be relevant to prognosis in PH patients. Third, subjects with risk factors for PH referred for right heart catheterization and a mild elevation in mPAP tend to present with increasing mPAP values and haemodynamic deterioration during follow-up compared to similar patients with normal mPAP.11, 12, 15 Fourth, and most importantly, a mild elevation of mPAP is associated with mortality.7-10, 13 It is equally important to note, however, that despite the reproducible association between mildly elevated mPAP and symptom or disease burden, proof of a causal relationship between pressure elevation and such clinical events is lacking currently. In fact, it may rather be the underlying pathology that leads to both increased mPAP and poor clinical outcome. There are probably four major reasons, which alone or in combination, explain a mild mPAP increase in most subjects (Figure 1).10 The differentiation of these causes is important at point of care, as each implicates different management and therapeutic approaches. Their short description is provided in Table 1.1, 6, 11, 15, 21-35 First, the most likely cause of a mild mPAP increase is left heart disease.8, 36 This may be frequently observed in elderly subjects suffering from heart failure with preserved or reduced ejection fraction. Second, a mild mPAP increase can often be observed in patients with lung diseases such as chronic obstructive pulmonary disease21, 28, 29 and lung fibrosis.6, 30-33 Third, early PVD, defined here as pulmonary vascular remodelling with haemodynamic consequences occurring in the absence of left heart or lung disease, may present with a mild elevation in mPAP and pulmonary vascular resistance. Patients with early PVD are of specific interest since even in the contemporary era, patients with pulmonary arterial hypertension (PAH) are frequently recognized in a late stage, although early diagnosis of the disease may lead to earlier initiation of specific therapy and better outcome.37 Fourth, from a statistical point of view, assuming a Gaussian distribution of mPAP, around 2.5% of all healthy subjects will have mPAP values > 20 mmHg.1 Most of these individuals will not be clinically assessed, but they may be encountered incidentally for other reasons. A recent European Respiratory Society Expert Statement suggested that an abnormal pulmonary haemodynamic response to exercise (exercise PH) may be defined as an increase in mPAP to > 30 mmHg and total pulmonary resistance to > 3 WU at maximal exercise.34, 38 A mild mPAP increase at rest appears to be closely related with exercise PH: in recent studies, 86% of patients with resting mPAP 21–24 mmHg17 and 75% of patients with chronic thromboembolic disease had exercise PH,39 while only 47% of patients with resting mPAP ≤ 20 mmHg fulfilled the criteria of exercise PH. As shown in Table 1, exercise PH is not specific for early PVD; the pattern of pulmonary haemodynamics during exercise may depend on the underlying condition, which also leads to a mild mPAP elevation at rest. In theory, cardiac, pulmonary, or pulmonary vascular limitations to exercise may be distinguished, but in reality, specific haemodynamic patterns corresponding to each of these causes of exercise intolerance are often difficult to recognize and, of course, combinations of these conditions may occur. As a mild increase in mPAP may be caused by different factors including left heart and lung diseases, the most important step is the recognition and optimal treatment of the underlying disease. In order to obtain reliable haemodynamic data, the importance of technically solid measurements cannot be overemphasized. The timely recognition of patients with early PVD is of great importance but not easy.40 As there are no published randomized controlled trials for the specific treatment of these subjects with PAH medications, currently no such treatment is generally recommended or approved. Close follow-up and, if possible, inclusion into clinical trials has been suggested.41 In specific subgroups, such as symptomatic patients with systemic sclerosis, PAH therapy may be initiated on an individual basis. Similarly, in patients with chronic thromboembolic disease and severe symptoms, pulmonary thromboendarterectomy, medical treatment or balloon angioplasty may be treatment options after careful consideration using an individualized care plan at an expert center.39 In order to improve clinical management of early PVD, we would highlight four areas where further research is needed. First, non-invasive methods should be optimized, so that patients with mildly elevated mPAP and early PVD can be recognized timely and effectively. Specific screening tools, including exercise testing, may be especially useful in patient groups at risk for the development of PVD, such as systemic sclerosis and patients with a familial predisposition to PAH. Second, prospective randomized controlled studies should be performed with current PAH drugs in patients with early PVD in order to assess whether haemodynamic deterioration can be prevented and clinical improvement achieved by drug therapy in this patient population. Such trials would also provide prospective data on the natural course of early PVD. Third, molecular mechanisms defining early PVD and a better understanding of progression towards more severe disease are needed to identify treatment targets that are specific to early-stage disease. Finally, investigating pulmonary vascular and right ventricular function including compliance and ventriculo–arterial coupling42 in early PVD may help understand the clinical deterioration of patients. Mild elevation of mPAP in the range between 20–25 mmHg is associated with increased mortality. A subgroup of these patients presents with early PVD and increased pulmonary vascular resistance and is associated with progressive haemodynamic deterioration. Currently, there are no approved drugs for this indication and randomized controlled trials are warranted before such therapy can be generally recommended. Conflict of interest: G.K. reports personal fees and non-financial support from Actelion, Bayer, GSK, MSD, Boehringer Ingelheim, Novartis, Chiesi and Vitalaire, outside the submitted work. P.D. reports personal fees and non-financial support from Actelion, non-financial support from Astra Zeneca, Bayer, GSK, m MSD, Novartis, Teva, Boehringer Ingelheim, Vifor and Menarini, outside the submitted work. R.C. reports personal fees from Actelion, Bayer and MSD, outside the submitted work. H.O. reports grants from Actelion, Roche, Boehringer, and Inventiva, personal fees and non-financial support from Astra Zeneca, Bayer, BMS, Boehringer, Chiesi, GSK, Menarini, MSD, Novartis, and Pfizer, outside the submitted work. B.A.M. has nothing to disclose." @default.
• W2968956918 created "2019-08-22" @default.
• W2968956918 creator A5013334062 @default.
• W2968956918 creator A5045540814 @default.
• W2968956918 creator A5060483520 @default.
• W2968956918 creator A5069317832 @default.
• W2968956918 creator A5077836810 @default.
• W2968956918 date "2019-08-13" @default.
• W2968956918 modified "2023-10-18" @default.
• W2968956918 title "Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?" @default.
• W2968956918 cites W120579310 @default.
• W2968956918 cites W1602490728 @default.
• W2968956918 cites W1951603230 @default.
• W2968956918 cites W1969490421 @default.
• W2968956918 cites W1981542159 @default.
• W2968956918 cites W2010245527 @default.
• W2968956918 cites W2022089821 @default.
• W2968956918 cites W2042146535 @default.
• W2968956918 cites W2069724928 @default.
• W2968956918 cites W2070897020 @default.
• W2968956918 cites W2074890748 @default.
• W2968956918 cites W2076025223 @default.
• W2968956918 cites W2080831548 @default.
• W2968956918 cites W2089858213 @default.
• W2968956918 cites W2096803041 @default.
• W2968956918 cites W2103313207 @default.
• W2968956918 cites W2113836310 @default.
• W2968956918 cites W2127994875 @default.
• W2968956918 cites W2133212072 @default.
• W2968956918 cites W2134620358 @default.
• W2968956918 cites W2293892392 @default.
• W2968956918 cites W2319106534 @default.
• W2968956918 cites W2492658578 @default.
• W2968956918 cites W2518436669 @default.
• W2968956918 cites W2562416809 @default.
• W2968956918 cites W2595015254 @default.
• W2968956918 cites W2606930738 @default.
• W2968956918 cites W2766767348 @default.
• W2968956918 cites W2766921809 @default.
• W2968956918 cites W2768919051 @default.
• W2968956918 cites W2773578061 @default.
• W2968956918 cites W2787232480 @default.
• W2968956918 cites W2791031797 @default.
• W2968956918 cites W2800029759 @default.
• W2968956918 cites W2888476660 @default.
• W2968956918 cites W2889468418 @default.
• W2968956918 cites W2891528059 @default.
• W2968956918 cites W2897262926 @default.
• W2968956918 cites W2904180601 @default.
• W2968956918 cites W2904321847 @default.
• W2968956918 doi "https://doi.org/10.1002/ejhf.1570" @default.
• W2968956918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31407852" @default.
• W2968956918 hasPublicationYear "2019" @default.
• W2968956918 type Work @default.
• W2968956918 sameAs 2968956918 @default.
• W2968956918 citedByCount "10" @default.
• W2968956918 countsByYear W29689569182020 @default.
• W2968956918 countsByYear W29689569182021 @default.
• W2968956918 countsByYear W29689569182022 @default.
• W2968956918 countsByYear W29689569182023 @default.
• W2968956918 crossrefType "journal-article" @default.
• W2968956918 hasAuthorship W2968956918A5013334062 @default.
• W2968956918 hasAuthorship W2968956918A5045540814 @default.
• W2968956918 hasAuthorship W2968956918A5060483520 @default.
• W2968956918 hasAuthorship W2968956918A5069317832 @default.
• W2968956918 hasAuthorship W2968956918A5077836810 @default.
• W2968956918 hasBestOaLocation W29689569181 @default.
• W2968956918 hasConcept C126322002 @default.
• W2968956918 hasConcept C164705383 @default.
• W2968956918 hasConcept C177713679 @default.
• W2968956918 hasConcept C2778198053 @default.
• W2968956918 hasConcept C2779134260 @default.
• W2968956918 hasConcept C2909878918 @default.
• W2968956918 hasConcept C2992779976 @default.
• W2968956918 hasConcept C71924100 @default.
• W2968956918 hasConcept C84393581 @default.
• W2968956918 hasConceptScore W2968956918C126322002 @default.
• W2968956918 hasConceptScore W2968956918C164705383 @default.
• W2968956918 hasConceptScore W2968956918C177713679 @default.
• W2968956918 hasConceptScore W2968956918C2778198053 @default.
• W2968956918 hasConceptScore W2968956918C2779134260 @default.
• W2968956918 hasConceptScore W2968956918C2909878918 @default.
• W2968956918 hasConceptScore W2968956918C2992779976 @default.
• W2968956918 hasConceptScore W2968956918C71924100 @default.
• W2968956918 hasConceptScore W2968956918C84393581 @default.
• W2968956918 hasIssue "9" @default.
• W2968956918 hasLocation W29689569181 @default.
• W2968956918 hasLocation W29689569182 @default.
• W2968956918 hasOpenAccess W2968956918 @default.
• W2968956918 hasPrimaryLocation W29689569181 @default.
• W2968956918 hasRelatedWork W2211649131 @default.
• W2968956918 hasRelatedWork W2331615205 @default.
• W2968956918 hasRelatedWork W2390856716 @default.
• W2968956918 hasRelatedWork W2416217541 @default.
• W2968956918 hasRelatedWork W2418895538 @default.
• W2968956918 hasRelatedWork W2604605908 @default.
• W2968956918 hasRelatedWork W2895926441 @default.
• W2968956918 hasRelatedWork W3028892750 @default.

• next